Telephone
61.3.9092.0480
Address
Suite 201 697 Burke Road Camberwell, Victoria (VIC) 3124
Description
Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its products include Pipeline, Trofinetide, and NNZ-2591. The company was founded on December 17, 2001 and is headquartered in Camberwell, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 6.72 - 16.4
Trade Value (12mth)
AU$1,742,738.00
1 week
4.12%
1 month
27.84%
YTD
80.21%
1 year
115.11%
All time high
16.4
EPS 3 yr Growth
-101.400%
EBITDA Margin
-10.90%
Operating Cashflow
$4m
Free Cash Flow Return
8.90%
ROIC
0.50%
Interest Coverage
N/A
Quick Ratio
25.80
Shares on Issue (Fully Dilluted)
130m
HALO Sector
Healthcare
Next Company Report Date
28-Feb-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.23
Date | Announcements |
---|---|
31 May 11 |
Neuren CEO Presentation to AGM
×
Neuren CEO Presentation to AGM |
31 May 11 |
Results of Annual Meeting
×
Results of Annual Meeting |
31 March 11 |
Annual Report to shareholders
×
Annual Report to shareholders |
31 March 09 |
Annual Report to shareholders
×
Annual Report to shareholders |
31 March 08 |
Annual Report to shareholders
×
Annual Report to shareholders |
31 March 06 |
Annual Report
×
Annual Report |
31 March 06 |
Notice of Annual General Meeting
×
Notice of Annual General Meeting |
31 July 23 |
Q2 2023 quarterly activity and cash flow report
×
Q2 2023 quarterly activity and cash flow report |
31 January 23 |
Q4 2022 quarterly activity and cash flow report
×
Q4 2022 quarterly activity and cash flow report |
31 January 22 |
Q4 2021 quarterly activity and cash flow report
×
Q4 2021 quarterly activity and cash flow report |
30 May 23 |
AGM Chair Address & CEO Presentation
×
AGM Chair Address & CEO Presentation |
30 May 23 |
Results of Meeting
×
Results of Meeting |
30 May 22 |
AGM Chairman's Address & CEO Presentation
×
AGM Chairman's Address & CEO Presentation |
30 May 22 |
Results of Meeting
×
Results of Meeting |
30 March 12 |
Neuren 2011 Annual Report
×
Neuren 2011 Annual Report |
30 March 10 |
Annual Report to shareholders
×
Annual Report to shareholders |
30 June 23 |
Neuren completes enrolment in Phelan-McDermid Phase 2 trial
×
Neuren completes enrolment in Phelan-McDermid Phase 2 trial |
30 July 13 |
Investor presentation July 2013
×
Investor presentation July 2013 |
29 May 17 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
29 May 08 |
CEO presentation to AGM
×
CEO presentation to AGM |
29 May 06 |
Further US Army results presented on NNZ-2566
×
Further US Army results presented on NNZ-2566 |
29 March 07 |
Annual Report
×
Annual Report |
29 June 20 |
AGM Chairman's Address and CEO Presentation
×
AGM Chairman's Address and CEO Presentation |
29 July 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
29 April 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
29 April 20 |
Annual Report 2019
×
Annual Report 2019 |
29 April 19 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.